In the second quarter of 2025, three Biologics companies received three FDA inspections in New Jersey, according to the U.S. Food and Drug Administration (FDA).
This was the lowest number of inspections per type of company made by the FDA in New Jersey, equalling 6.1% of all inspections in the second quarter of 2025.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality.
| Project Area | No Action Indicated | Voluntary Action Indicated | Official Action Indicated |
|---|---|---|---|
| Bioresearch Monitoring | 2 | — | — |
| Blood and Blood Products | 2 | — | — |
| Compliance: Devices | 1 | 1 | — |
| Drug Quality Assurance | 1 | 2 | 2 |
| Food Composition, Standards, Labeling and Econ | 14 | 2 | — |
| Foodborne Biological Hazards | 21 | 13 | — |
| Human Cellular, Tissue, and Gene Therapies | 1 | — | — |
| Postmarket Assurance: Devices | 2 | — | — |
